ArticlePCN reports : psychiatry and clinical neurosciences2025
Electroconvulsive therapy for Parkinson's disease-related apathy: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electroconvulsive therapy for Parkinson's disease-related apathy: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonmotor symptoms are a critical focus in the management of Parkinson's disease (PD). Apathy is defined as a quantitative reduction in goal-directed activity, characterized by diminished initiative, interest, and emotional expression or responsiveness. It affects approximately 40% of patients with PD, severely impairing daily functioning and quality of life. Although electroconvulsive therapy (ECT) is well established for alleviating depressive symptoms in patients with PD, its efficacy in treating apathy remains largely unexplored. Case Presentation: We report the case of a 54-year-old man diagnosed with PD at age 49, whose motor symptoms were well controlled with optimized pharmacotherapy. However, at age 53, he developed profound apathy, characterized by a notable reduction in spontaneous movement and emotional expression. Given the lack of response to pharmacological adjustments, including a trial of venlafaxine, modified ECT (m-ECT) was initiated. The patient underwent 10 m-ECT sessions over 5 weeks (twice weekly) using propofol and succinylcholine. Following treatment, his apathy scale score improved substantially from 32 to 12, with no adverse effects on cognitive function. Conclusion: This case highlights the potential efficacy of ECT for PD-related apathy. Further research is needed to elucidate its underlying mechanisms and assess the long-term outcomes of ECT in managing nonmotor symptoms in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.